NANOVIRICIDES, INC. 8-K

What Happened NanoViricides, Inc. (NNVC) filed an 8-K (Item 7.01, Regulation FD Disclosure) on May 21, 2026 reporting comments made by President and Executive Chairman Dr. Anil R. Diwan at the Alliance Global Partners (AGP) Healthcare Companies Showcase on May 20, 2026. In a fireside chat with Dr. James Molloy (A.G.P.), Dr. Diwan described two drug candidates — NV-387 (a broad‑spectrum antiviral) and NV-387 encapsulating remdesivir (the company’s back-up candidate) — and said both are expected by the company to be effective against the current Bundibugyo Ebola strain in the Democratic Republic of Congo (DRC). He noted NV-387 is entering a Phase II clinical trial against mpox in the DRC, and that NanoViricides maintains a clinical site there.

Key Details

• Event and filing: AGP Healthcare Showcase on May 20, 2026; 8-K filed May 21, 2026 under Item 7.01 (Regulation FD Disclosure).
• Candidates discussed: NV-387 (primary) and NV-387 encapsulating remdesivir (back-up).
• Clinical status/location: NV-387 entering Phase II trial for mpox in the DRC; company has a clinical site in DRC.
• Context on remdesivir: prior Ebola clinical trial established safety/tolerability but not efficacy; company says remdesivir was active in animal models and that encapsulation in NV-387 improves stability and oral formulation (peer‑reviewed work cited, e.g., PLOS One).

Why It Matters This disclosure informs investors about management’s public statements on the company’s development programs and potential applicability of its candidates to the ongoing Ebola outbreak in DRC. Key takeaways for investors: NNVC is publicly positioning NV-387 (and an NV-387/remdesivir combo) as candidates the company believes could address the Bundibugyo strain, NV-387 is advancing to Phase II for mpox with an on‑site presence in the DRC, and the company cites prior peer‑reviewed work and prior remdesivir human safety data as part of its rationale. The 8-K is a Regulation FD disclosure of those remarks; it does not change clinical status or regulatory approvals.